|
|
Post by cretin11 on Mar 17, 2021 19:04:21 GMT -5
Thanks for the thorough recap by Chris and others. Some encouraging tidbits there, not the least of which is MC admitting the Afrezza dosing failures and seeming to recognize that working with VDEX could be the ticket to successfully boosting scripts. If ego is put to the side, better late than never and kudos to him if he indeed does this.
|
|
|
|
Post by sportsrancho on Mar 17, 2021 19:07:50 GMT -5
Much respect ...if that is the case, a lot of respect just for admitting that they didn’t get it right in the first place. ❤️ Which is the first step to fixing it.
|
|
|
|
Post by sportsrancho on Mar 17, 2021 20:12:19 GMT -5
Just an afterthought and this is just an assumption on my part but I think they knew it wasn’t correct, ) but not to the extent that it wasn’t correct ) in the first place ...but they didn’t think it would matter that much, but as time has gone on and the results have come out from the people that have been dosed for optimal results the difference is striking. And those results are what make Afrezza a game changer.
|
|
|
|
Post by Chris-C on Mar 17, 2021 20:14:30 GMT -5
Much respect ...if that is the case, a lot of respect just for admitting that they didn’t get it right in the first place. ❤️ Which is the first step to fixing it. Exactly. I appreciated his candor and humility. I have to say, Sports, when he was discussing ways to enhance Afrezza patient support and scripts, everything he described reminded me of the VDEX model (as I understand it). It would be great if some sort of deal could be worked out to "test the model" but I have no expertise around regulatory issues and other legalities that bear upon such relationships between "clinics" and pharmaceutical companies. It seems to me that if patient education and support is what is needed (and the company seems to agree that this is crucial), then disruptive technologies deserve out of the box marketing and distribution strategies, whether this involves VDEX, or any and all others. I was encouraged that he seemed open to the idea. I found it interesting that MC seemed to say that after MNKD's analysis of their subsidy approach to covering out of pocket costs for first time users, they concluded that it was financially unsustainable and a better approach was tackling prior authorizations and denials head on. |
|
|
|
Post by sportsrancho on Mar 17, 2021 20:19:01 GMT -5
Right and you’ve seen how quickly the Vdex model can get their A1 C down and then challenge the insurance company.( With the right protocols.)
|
|
|
|
Post by cretin11 on Mar 17, 2021 20:25:17 GMT -5
It’s extremely encouraging. If anyone goes back and watches/reads the Bill McCullough youtube messages and emails/letters, they will see that he was on the money pretty much from the get go. Hindsight is 20/20 so now hopefully MC and others at MNKD see it now. A collaboration between VDEX and MNKD would be such a win-win, as some have been saying for a while.
|
|
|
|
Post by buyitonsale on Mar 17, 2021 21:01:16 GMT -5
When MC talked about a new care model today, what are the chances that this model involves Vdex collaboration ?
Not that it would be a bad idea, but most likely there is no connection.
I do not think any drug manufacturer can be directly involved in prescribing, so the clinic idea is far fetched.
I can see something along the line where Mankind provides Afrezza Assist services to prescribers to provide help with PA and patient education, on a larger scale then they do now.
|
|
|
|
Post by letitride on Mar 17, 2021 21:04:59 GMT -5
I heard it all and my biggest takeaway is there's a lot going on and we got the nut to make it happen.
Lets Go!
|
|
|
|
Post by mytakeonit on Mar 17, 2021 22:20:31 GMT -5
I'm just glad that Mike C didn't say at 15:21 that I really should buy the last 35k shares so I REALLY would be at 1M ...  But, that's mytakeonit |
|
|
|
Post by longliner on Mar 17, 2021 23:18:59 GMT -5
I'm just glad that Mike C didn't say at 15:21 that I really should buy the last 35k shares so I REALLY would be at 1M ... But, that's mytakeonit That was exactly what he said!!! At dawn! Well, dawn Island time soooo let's call it noon.  |
|
|
|
Post by prcgorman2 on Mar 18, 2021 6:41:51 GMT -5
Much respect ...if that is the case, a lot of respect just for admitting that they didn’t get it right in the first place. ❤️ Which is the first step to fixing it. Exactly. I appreciated his candor and humility. I have to say, Sports, when he was discussing ways to enhance Afrezza patient support and scripts, everything he described reminded me of the VDEX model (as I understand it). It would be great if some sort of deal could be worked out to "test the model" but I have no expertise around regulatory issues and other legalities that bear upon such relationships between "clinics" and pharmaceutical companies. It seems to me that if patient education and support is what is needed (and the company seems to agree that this is crucial), then disruptive technologies deserve out of the box marketing and distribution strategies, whether this involves VDEX, or any and all others. I was encouraged that he seemed open to the idea. I found it interesting that MC seemed to say that after MNKD's analysis of their subsidy approach to covering out of pocket costs for first time users, they concluded that it was financially unsustainable and a better approach was tackling prior authorizations and denials head on.Chris-C - “...tackling Prior Authorizations and denials head on”. What does that mean? (I haven’t tried to find/listen to the presentation.) To me it would mean negotiating discounts with PBMs, but I suspect it means putting butts in seats whose job is to work at, rather than with, the insurers. I’ve no idea what the discounts on Afrezza would need to be and whether those would be even less sustainable than subsidies covering out-of-pocket costs. If discounts to PBMs are unattainable, and I’ve presumed that is the case since Mannkind has apparently never taken that path, I would appreciate that being plainly stated by Dr. Castagna, and that he be explicit about how out-of-bounds that is. Insurance is based on risk management and spreading risks across a population of subscribers so that those with more expensive requirements benefit from those with less requirements and managing to the change in requirements of the demographics of the subscribers over time. The impact of Boomers has been anticipated for a long time. So, if discounts can’t be on par with cheaper insulin products, than Afrezza has to be proven cheaper to the insurance companies, over time. It is all about the safety and efficacy, but my gut (which also told me to buy a lot of MNKD shares) says safety, safety, SAFETY! Collect information on Afrezza patients’ trips to the emergency rooms and hospitalizations for hypoglycemic events, and prove the corrolary to neuropathy treatment, and shove it in the faces of the actuaries. Are the insurance companies looking at a 5 year horizon or 50? Want to think outside the box? Do it. What is their box? Redefine their frame of reference. |
|
|
|
Post by liane on Mar 18, 2021 6:46:22 GMT -5
Mike stated that many of the denials are easy to fix - for instance - physicians were not documenting that a patient had failed on standard therapy. All it would take is documenting that the patient was already on standard therapy for an appropriate period of time and their A1C was not at goal.
|
|
|
|
Post by goyocafe on Mar 18, 2021 7:14:31 GMT -5
Mike stated that many of the denials are easy to fix - for instance - physicians were not documenting that a patient had failed on standard therapy. All it would take is documenting that the patient was already on standard therapy for an appropriate period of time and their A1C was not at goal. The fact that PAs dominate the discussion about scripts is the telling fact that there are bigger issues at foot. Mainly crappy label, rigged health insurance system, a lack of published data (we’ve been promised for years and MC is still talking about it even after David Kendall had a swing at it), a biased American Diabetes Association, but it’s on MC to demonstrate superiority, and until then they’ll continue to list Afrezza below bariatric surgery on the recommended options list. So whittle away at prior authorizations, since it’s all MC can do, but it’s akin to scraping barnacles off the Titanic. |
|
|
|
Post by boca1girl on Mar 18, 2021 8:52:53 GMT -5
What is the Peach study? Is that the Peds trial?
From yesterday’s transcript, Mike said:
“We spent a lot of time in the last three years doing new studies to show retrospectively what our data showed, as well as prospectively, and now we're taking that data set. We're using that for our upcoming PEACH [ph] trial. We're using it for the trial in India.”
|
|
|
|
Post by sayhey24 on Mar 18, 2021 9:35:28 GMT -5
Much respect ...if that is the case, a lot of respect just for admitting that they didn’t get it right in the first place. ❤️ Which is the first step to fixing it. Good Grief - we have been telling Mike this since the first time I ever met the guy and I am sure Bill has too. Back in the day Mike was the chief marketing guy. Calling the cartridges "units" was IMO the biggest marketing blunder Al Mann ever made and IMO has retarded adoption. I understand Al was trying to address the Exubera dosing mess and thought calling them "units" would make things simple but instead it resulted in doctors trying tp compare afrezza to the RAAs and it has resulted in dose conversions and stacking fears and all the rest. If the cartridges are relabeled to small, medium and large it would provide a new paradigm for dosing and concerns about second and even third dosing should be eliminated as the doctors will no longer try to compare to RAAs. |
|
